Summary
15.69 0.04(0.22%)09/06/2024
Inmode Ltd (INMD)
Inmode Ltd (INMD)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.26 | -6.30 | -7.11 | -14.50 | -30.98 | -60.19 | 29.95 | 131.17 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 15.69 | |
| Open | 15.64 | |
| High | 15.85 | |
| Low | 15.46 | |
| Volume | 617,935 | |
| Change | 0.04 | |
| Change % | 0.26 | |
| Avg Volume (20 Days) | 739,625 | |
| Volume/Avg Volume (20 Days) Ratio | 0.84 | |
| 52 Week Range | 15.39 - 39.48 | |
| Price vs 52 Week High | -60.27% | |
| Price vs 52 Week Low | 1.92% | |
| Range | 0.29 | |
| Gap Up/Down | -0.18 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,327 | |
| EBIDTA | 149,252,000 | |
| PE Ratio | 37.6152 | |
| PEG Ratio | 2.4277 | |
| WallStreet Target Price | 98.50 | |
| Book Value | 4.6430 | |
| Earnings Per Share | 1.7360 | |
| EPS Estimate Current Quarter | 0.5000 | |
| EPS Estimate Next Quarter | 0.5100 | |
| EPS Estimate Current Year | 1.9400 | |
| EPS Estimate Next Year | 2.0600 | |
| Diluted EPS (TTM) | 1.7360 | |
| Revenues | ||
| Profit Marging | 0.4606 | |
| Operating Marging (TTM) | 0.4617 | |
| Return on asset (TTM) | 0.2576 | |
| Return on equity (TTM) | 0.4820 | |
| Revenue TTM | 322,212,000 | |
| Revenue per share TTM | 4.0560 | |
| Quarterly Revenue Growth (YOY) | 0.5770 | |
| Quarterly Earnings Growth (YOY) | 0.8250 | |
| Gross Profit (TTM) | 175,258,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 37.6152 | |
| Forward PE | 33.5570 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 13.8261 | |
| Revenue Enterprise Value | 15.2223 | |
| EBITDA Enterprise Value | 32.8626 | |
| Shares | ||
| Shares Outstanding | 76,381,696 | |
| Shares Float | 53,933,585 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 34.86 | |
| Institutions (%) | 62.95 | |
09/06 04:38 EST - seekingalpha.com
InMode Stock: An Inverse Bubble Caused By Short-Term Trouble
InMode stock has significant upside potential due to its low valuation, profitability, share buybacks, and potential benefits from expected interest rate cuts. INMD's business model involves selling high-quality, expensive medical devices for aesthetic procedures, heavily influenced by interest rates due to customer financing. The stock's decline was driven by underutilized buybacks, declining revenue, and high interest rates, but recent buybacks and potential rate cuts offer a brighter outlook.
InMode Stock: An Inverse Bubble Caused By Short-Term Trouble
InMode stock has significant upside potential due to its low valuation, profitability, share buybacks, and potential benefits from expected interest rate cuts. INMD's business model involves selling high-quality, expensive medical devices for aesthetic procedures, heavily influenced by interest rates due to customer financing. The stock's decline was driven by underutilized buybacks, declining revenue, and high interest rates, but recent buybacks and potential rate cuts offer a brighter outlook.
09/04 08:30 EST - prnewswire.com
InMode to Present at 2024 Baird Global Healthcare Conference
YOKNEAM, Israel , Sept. 4, 2024 /PRNewswire/ -- InMode Ltd.
InMode to Present at 2024 Baird Global Healthcare Conference
YOKNEAM, Israel , Sept. 4, 2024 /PRNewswire/ -- InMode Ltd.
08/06 08:30 EST - prnewswire.com
InMode to Present at Upcoming Investor Conferences
YOKNEAM, Israel , Aug. 6, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in August: 9th Annual Needham Virtual MedTech & Diagnostics Conference Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer Format: Virtual one-on-one meetings When: Monday, Aug. 12 Canaccord 44th Annual Global Growth Conference Presenters: Yair Malca, Chief Financial Officer Format: In-person fireside chat moderated by Caitlin Cronin, Director of MedTech Equity Research, and meetings When: Wednesday, Aug. 14 at 2:00 pm ET A live webcast of the presentation can be accessed here.
InMode to Present at Upcoming Investor Conferences
YOKNEAM, Israel , Aug. 6, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in August: 9th Annual Needham Virtual MedTech & Diagnostics Conference Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer Format: Virtual one-on-one meetings When: Monday, Aug. 12 Canaccord 44th Annual Global Growth Conference Presenters: Yair Malca, Chief Financial Officer Format: In-person fireside chat moderated by Caitlin Cronin, Director of MedTech Equity Research, and meetings When: Wednesday, Aug. 14 at 2:00 pm ET A live webcast of the presentation can be accessed here.
08/01 11:19 EST - seekingalpha.com
InMode Ltd. (INMD) Q2 2024 Earnings Call Transcript
Start Time: 08:30 January 1, 0000 9:07 AM ET InMode Ltd. (NASDAQ:INMD ) Q2 2024 Earnings Conference Call August 01, 2024, 08:30 AM ET Company Participants Moshe Mizrahy - CEO Michael Kreindel - Co-Founder and Chief Technology Officer Yair Malca - CFO Shakil Lakhani - President, North America Eran Krieger - Medical Director and VP of Medical Affairs Rafael Lickerman - Vice President, Finance Miri Segal - CEO, MS-IR Conference Call Participants Danielle Antalffy - UBS Caitlin Cronin - Canaccord Genuity Jeff Johnson - Baird Joseph Conway - Needham and Company Operator Good day, and welcome to InMode's Second Quarter 2024 Earnings Results Conference Call.
InMode Ltd. (INMD) Q2 2024 Earnings Call Transcript
Start Time: 08:30 January 1, 0000 9:07 AM ET InMode Ltd. (NASDAQ:INMD ) Q2 2024 Earnings Conference Call August 01, 2024, 08:30 AM ET Company Participants Moshe Mizrahy - CEO Michael Kreindel - Co-Founder and Chief Technology Officer Yair Malca - CFO Shakil Lakhani - President, North America Eran Krieger - Medical Director and VP of Medical Affairs Rafael Lickerman - Vice President, Finance Miri Segal - CEO, MS-IR Conference Call Participants Danielle Antalffy - UBS Caitlin Cronin - Canaccord Genuity Jeff Johnson - Baird Joseph Conway - Needham and Company Operator Good day, and welcome to InMode's Second Quarter 2024 Earnings Results Conference Call.
08/01 09:15 EST - zacks.com
InMode (INMD) Q2 Earnings and Revenues Top Estimates
InMode (INMD) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.72 per share a year ago.
InMode (INMD) Q2 Earnings and Revenues Top Estimates
InMode (INMD) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.72 per share a year ago.
08/01 07:00 EST - prnewswire.com
InMode Reports Second Quarter 2024 Financial Results; Quarterly Revenue of $86.4M Represents 36.5% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet delivered) of $102.6M
YOKNEAM, Israel, Aug. 1, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2024.
InMode Reports Second Quarter 2024 Financial Results; Quarterly Revenue of $86.4M Represents 36.5% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet delivered) of $102.6M
YOKNEAM, Israel, Aug. 1, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2024.
07/31 08:03 EST - prnewswire.com
InMode Introduces IgniteRF The Complete Minimally Invasive Soft Tissue Contraction Platform
IRVINE, Calif. , July 31, 2024 /PRNewswire/ -- InMode Ltd.
InMode Introduces IgniteRF The Complete Minimally Invasive Soft Tissue Contraction Platform
IRVINE, Calif. , July 31, 2024 /PRNewswire/ -- InMode Ltd.
07/25 11:08 EST - zacks.com
Analysts Estimate InMode (INMD) to Report a Decline in Earnings: What to Look Out for
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate InMode (INMD) to Report a Decline in Earnings: What to Look Out for
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/25 08:15 EST - prnewswire.com
DOMA Perpetual Sends Letter to the Board of Directors of InMode Urging the Execution of a 40% Tender Offer
Believes InMode's Cash Balance of Roughly 55% of its Market Cap is Grossly Inefficient Asserts the Current Valuation Offers an Unprecedented Opportunity to Create Shareholder Return MIAMI , July 25, 2024 /PRNewswire/ -- DOMA Perpetual Capital Management LLC today sent a letter to the Board of Directors of InMode (NYSE: INMD) urging the Board to execute a 40% tender offer of the stock. The letter can be downloaded here.
DOMA Perpetual Sends Letter to the Board of Directors of InMode Urging the Execution of a 40% Tender Offer
Believes InMode's Cash Balance of Roughly 55% of its Market Cap is Grossly Inefficient Asserts the Current Valuation Offers an Unprecedented Opportunity to Create Shareholder Return MIAMI , July 25, 2024 /PRNewswire/ -- DOMA Perpetual Capital Management LLC today sent a letter to the Board of Directors of InMode (NYSE: INMD) urging the Board to execute a 40% tender offer of the stock. The letter can be downloaded here.
07/17 08:03 EST - prnewswire.com
Morpheus8 Secures First and Only FDA Clearance for Soft Tissue Contraction for Fractional Radiofrequency Microneedling
IRVINE, Calif. , July 17, 2024 /PRNewswire/ -- InMode Ltd.
Morpheus8 Secures First and Only FDA Clearance for Soft Tissue Contraction for Fractional Radiofrequency Microneedling
IRVINE, Calif. , July 17, 2024 /PRNewswire/ -- InMode Ltd.
07/11 08:30 EST - prnewswire.com
InMode to Report Second Quarter 2024 Financial Results and Hold Conference Call on Aug. 1, 2024
Expects Q2 Revenue Between $86.2M-$86.3M, Pro-Forma Revenue (including new platform pre-orders) Between $102.4M-$102.5M, Decreases FY 2024 Guidance to $430M-$440M Conference call to be held on Thursday, Aug. 1, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, July 11, 2024 /PRNewswire/ -- InMode Ltd.
InMode to Report Second Quarter 2024 Financial Results and Hold Conference Call on Aug. 1, 2024
Expects Q2 Revenue Between $86.2M-$86.3M, Pro-Forma Revenue (including new platform pre-orders) Between $102.4M-$102.5M, Decreases FY 2024 Guidance to $430M-$440M Conference call to be held on Thursday, Aug. 1, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, July 11, 2024 /PRNewswire/ -- InMode Ltd.
07/01 06:00 EST - investorplace.com
3 MedTech Stocks to Buy for Healthy Gains
Fundamentally, few sectors exist outside of the broad healthcare umbrella that offer what I would term permanent relevance. In this case, the concept of caring for other people is likely an eternal one.
3 MedTech Stocks to Buy for Healthy Gains
Fundamentally, few sectors exist outside of the broad healthcare umbrella that offer what I would term permanent relevance. In this case, the concept of caring for other people is likely an eternal one.
06/13 11:49 EST - seekingalpha.com
InMode: Reversing Previous Shareholder Dilution With Buybacks
Shareholders of InMode Ltd. have seen a 46% decline in value due to slowing sales and capital allocation uncertainties. Sales growth has been impacted by rising interest rates affecting leasing deals, leading to lower revenue growth projections for 2024. The company's new share repurchase program should reverse the dilution shareholders previously experienced.
InMode: Reversing Previous Shareholder Dilution With Buybacks
Shareholders of InMode Ltd. have seen a 46% decline in value due to slowing sales and capital allocation uncertainties. Sales growth has been impacted by rising interest rates affecting leasing deals, leading to lower revenue growth projections for 2024. The company's new share repurchase program should reverse the dilution shareholders previously experienced.
05/16 08:00 EST - prnewswire.com
InMode to Present at Jefferies Healthcare Conference
YOKNEAM, Israel , May 16, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer, will present in-person at the Jefferies Healthcare Conference in New York on June 5, 2024.
InMode to Present at Jefferies Healthcare Conference
YOKNEAM, Israel , May 16, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer, will present in-person at the Jefferies Healthcare Conference in New York on June 5, 2024.
05/08 08:03 EST - prnewswire.com
InMode Announces P1 Offshore Racing Partnership with Female Driver Victoria Rand
IRVINE, Calif. , May 8, 2024 /PRNewswire/ -- InMode Ltd.
InMode Announces P1 Offshore Racing Partnership with Female Driver Victoria Rand
IRVINE, Calif. , May 8, 2024 /PRNewswire/ -- InMode Ltd.
05/02 10:31 EST - zacks.com
InMode (INMD) Q1 Earnings and Revenues Beat Estimates
InMode (INMD) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.40 per share. This compares to earnings of $0.52 per share a year ago.
InMode (INMD) Q1 Earnings and Revenues Beat Estimates
InMode (INMD) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.40 per share. This compares to earnings of $0.52 per share a year ago.
05/02 07:00 EST - prnewswire.com
InMode Reports First Quarter 2024 Financial Results; Quarterly Revenue of $80.3M Represents 24% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet available) of $96M;
Company Announces Share Repurchase Program of Up to 8.37 Million Shares; and Appoints New Chairman of the Board of Directors YOKNEAM, Israel, May 2, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2024.
InMode Reports First Quarter 2024 Financial Results; Quarterly Revenue of $80.3M Represents 24% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet available) of $96M;
Company Announces Share Repurchase Program of Up to 8.37 Million Shares; and Appoints New Chairman of the Board of Directors YOKNEAM, Israel, May 2, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2024.
04/25 11:07 EST - zacks.com
Earnings Preview: InMode (INMD) Q1 Earnings Expected to Decline
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: InMode (INMD) Q1 Earnings Expected to Decline
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/15 15:15 EST - accesswire.com
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 15, 2024 in InMode Lawsuit - INMD
NEW YORK, NY / ACCESSWIRE / April 15, 2024 / If you suffered a loss on your InMode Ltd. (NASDAQ:INMD) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inmode-lawsuit-submission-form?prid=75664&wire=1 or contact Joseph E.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 15, 2024 in InMode Lawsuit - INMD
NEW YORK, NY / ACCESSWIRE / April 15, 2024 / If you suffered a loss on your InMode Ltd. (NASDAQ:INMD) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inmode-lawsuit-submission-form?prid=75664&wire=1 or contact Joseph E.
04/15 14:43 EST - prnewswire.com
INMD DEADLINE TODAY: ROSEN, LEADING TRIAL ATTORNEYS, Encourages InMode Ltd. Investors to Secure Counsel Before Important April 15 Deadline in Securities Class Action - INMD
NEW YORK , April 15, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of InMode Ltd. (NASDAQ: INMD) between June 4, 2021 and October 12, 2023, both dates inclusive (the "Class Period"), of the important April 15, 2024 lead plaintiff deadline.
INMD DEADLINE TODAY: ROSEN, LEADING TRIAL ATTORNEYS, Encourages InMode Ltd. Investors to Secure Counsel Before Important April 15 Deadline in Securities Class Action - INMD
NEW YORK , April 15, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of InMode Ltd. (NASDAQ: INMD) between June 4, 2021 and October 12, 2023, both dates inclusive (the "Class Period"), of the important April 15, 2024 lead plaintiff deadline.